Literature DB >> 19837288

Plague.

E D Williamson1.   

Abstract

Killed whole cell vaccines for plague were first produced as long ago as the late 1890s and modified versions of these are still used, with evidence that they are efficacious against bubonic plague. Renewed efforts with modern technology have yielded new candidate vaccines which are less reactogenic, can be produced in a conventional pharmaceutical manufacturing plant and are protective against the life-threatening pneumonic form of the disease. This paper reviews the progress towards an improved vaccine for plague and assesses the likely impact of a prophylactic vaccine for bubonic and pneumonic plague.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19837288     DOI： 10.1016/j.vaccine.2009.07.068

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  31 in total

1.  Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Authors:  Devender Kumar; Girish Kirimanjeswara; Dennis W Metzger
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

2.  One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.

Authors:  Jialei Hu; Lei Jiao; Yuemei Hu; Kai Chu; Jingxin Li; Fengcai Zhu; Taishun Li; Zhiyuan Wu; Dong Wei; Fanyue Meng; Bingxiang Wang
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

3.  Physiological levels of glucose induce membrane vesicle secretion and affect the lipid and protein composition of Yersinia pestis cell surfaces.

Authors:  Anna M Kolodziejek; Allan B Caplan; Gregory A Bohach; Andrzej J Paszczynski; Scott A Minnich; Carolyn J Hovde
Journal:  Appl Environ Microbiol       Date:  2013-05-17       Impact factor: 4.792

4.  Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.

Authors:  Paul M Arnaboldi; Mariya Sambir; Christina D'Arco; Lauren A Peters; Jos F M L Seegers; Lloyd Mayer; Alison A McCormick; Raymond J Dattwyler
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

5.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

6.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

7.  Establishment of a Swiss Webster mouse model of pneumonic plague to meet essential data elements under the animal rule.

Authors:  Patricia Fellows; Winston Lin; Carol Detrisac; Shu-Chieh Hu; Narayanan Rajendran; Bruce Gingras; Louis Holland; Jessica Price; Mark Bolanowski; Robert V House
Journal:  Clin Vaccine Immunol       Date:  2012-02-15

Review 8.  Plague gives surprises in the first decade of the 21st century in the United States and worldwide.

Authors:  Thomas Butler
Journal:  Am J Trop Med Hyg       Date:  2013-09-16       Impact factor: 2.345

Review 9.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

10.  New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Authors:  Jourdan A Andersson; Eric C Fitts; Michelle L Kirtley; Duraisamy Ponnusamy; Alex G Peniche; Sara M Dann; Vladimir L Motin; Sadhana Chauhan; Jason A Rosenzweig; Jian Sha; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.